Discounted Cash Flow Calculation for GTSM:4167 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Note: Free cash flow to equity valuations ignore the company's cash or debt.
GTSM:4167 DCF 1st Stage: Next 10 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Savior Lifetec's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Savior Lifetec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Savior Lifetec's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Savior Lifetec's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to compare Savior Lifetec's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to determine if Savior Lifetec is high growth as no earnings estimate data is available.
Unable to determine if Savior Lifetec is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Savior Lifetec's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. M. Sherry Ku, Ph.D. serves as the Chief Executive Officer at Savior Lifetec Corporation since 2014 and served as its Chairman since 2014 until 2018. Dr. Ku served as the Head of Early Pharmaceutical Development at Wyeth/Lederle (now Pfizer), overseeing discovery interface through clinical proof of concept. During her 20-year tenure, she oversaw new drug development for over 170 new clinical leads resulting in 85 original NME IND filings. She also developed 8 commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil and Bosulif, three of which are antibiotics. Zosyn, in particular, remains as one of the three lifesaving injectable antibiotics in the hospital worldwide. She was in charge of a penem facility and has early exposure to carbapenems via participation in the development of Biapenem with Lederle Japan/Takeda. She often leads the effort in New Drug Application and is responsible for FDA PAI activities. In 2009, Dr. Ku joined TWi Pharma as its Chief Scientific Officer and President, filing 6 high barrier ANDAs and establishing a pipeline of 6 new drugs which included 3 biologic drugs. In 2012, she co-founded Ruen Huei Biopharmaceutical Company and served as its President. Dr. Ku received her B.S. in Pharmaceutical Chemistry from National Taiwan University. She then earned a Ph.D. in Pharmaceutical Chemistry at the Ohio State University.
Insufficient data for M. to compare compensation growth.
Insufficient data for M. to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Chief Executive Officer
Board of Directors
Chairwoman of the Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent for intravenous infusion; and meropenem, a beta-lactamase resistant carbapenem antibiotic for parenteral administration, as well as meropenem and sodium carbonate. It also provides ertapenem, a new form of carbapenem for use on gram-negative and gram-positive anaerobes and aerobic. The company’s pipeline products include SLC-006 for prostate cancer endometriosis uterine leiomyoma; and sterile paliperidone palmitate API for the treatment of schizophrenia. Savior Lifetec Corporation was founded in 2004 and is headquartered in Miaoli County, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.